Category: Press Release - Page 10 - Psychedelic Alpha

Read more about the article Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Post published:July 5, 2023
Post category:Press Release

Read more about the article FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC.

FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC.

Post published:June 30, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Post published:June 29, 2023
Post category:Press Release

Read more about the article Numinus to Host Q3 2023 Results Conference Call on July 17, 2023

Numinus to Host Q3 2023 Results Conference Call on July 17, 2023

Post published:June 29, 2023
Post category:Press Release

Read more about the article Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights

Post published:June 28, 2023
Post category:Press Release

Read more about the article PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA

Post published:June 27, 2023
Post category:Press Release

Read more about the article BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives

Post published:June 27, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Post published:June 27, 2023
Post category:Press Release

Read more about the article BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada

BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada

Post published:June 22, 2023
Post category:Press Release

Read more about the article Numinus Announces Agreement with HealingMaps to Drive Strategic Clinic Growth

Numinus Announces Agreement with HealingMaps to Drive Strategic Clinic Growth

Post published:June 22, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.